Stevanato Group Stock Plunges 26% as Weak Order Intake and Cautious 2027 Outlook Overshadow Revenue Beat
Stevanato Group (STVN) shares dropped 26% after reporting Q3 revenue growth of 8% to 326.1M euros, beating expectations, but providing a cautious 2027 outlook with low single-digit revenue growth. Adjusted EPS was 16 euro cents, in line with estimates. The company's market value fell to $4B. GLP-1 therapy revenue was 17-18% of total revenue, with other biologics growing over 30%. The Engineering segment saw a 12% revenue decline.
How this was made
The 30-second read
Why it matters
The key new information is the cautious 2027 growth outlook plus signed-order intake below targets, which the article links to the sharp selloff despite a Q3 revenue beat.
Market read
Traders should focus on whether order intake rebounds and whether non-GLP-1 biologics growth can sustain overall revenue growth into 2027.
What to watch
Non-GLP-1 biologics revenue grew more than 30%, which could offset GLP-1 softness if order intake recovers faster than the market assumes.
Background
Stevanato supplies glass vials, syringes, cartridges, and drug delivery systems, with GLP-1 therapies contributing about 17% to 18% of Q3 revenue.
Ticker impact
Stevanato shares plunged after it guided 2027 to only low single-digit revenue growth and said new order intake missed targets.
Likely downside pressure as investors reprice 2027 growth and order recovery risk.
The article attributes the 26% drop to the 2027 outlook and order intake coming in below targets, which directly changes forward expectations.
Market effects
Highlights sensitivity of injectable-drug supply-chain names to GLP-1 demand expectations and order-flow momentum.
US-listed Italian med-tech supplier selloff may spill into European pharma packaging peers on guidance sensitivity.
Signals broader caution toward GLP-1-linked capex and equipment/order cycles tied to injectable drug manufacturing.
Counterpoint
The quarter still beat on revenue and margins, and management says Engineering operations stabilized, so the selloff may over-discount near-term execution.
Key entities
- public_companyStevanato Group
Italian drug-container and delivery systems maker whose stock dropped sharply on cautious 2027 outlook and weaker order intake.
- executiveFranco Stevanato
CEO and Chairman quoted saying Q3 results were in line with expectations.
